Kyprolis

June 11, 2018

Amgen, MD Anderson Collaborate to Advance Early-stage Treatments for Myeloma, Other Cancers

News

Two multi-year collaborative agreements were recently established by Amgen and the University of Texas MD Anderson Cancer Center to advance the development of early-stage investigative therapies in Amgen’s portfolio ... Read more

January 12, 2018January 12, 2018

Multiple Myeloma Patients Remain On Treatment Far Less than in Clinical Trials, Study Finds

News

Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter than those participating in clinical trials, a study found. ... Read more

November 27, 2017November 27, 2017

Adaptive Biotechnologies, Amgen Partner in Phase 3 CANDOR Trial for Multiple Myeloma

News

Adaptive Biotechnologies has partnered with Amgen to use Adaptive’s NGS-based clonoSEQ Assay in a Phase 3 clinical trial led by Amgen to measure minimal residual disease (MRD) status in ... Read more

October 30, 2017October 30, 2017

Pomalyst Is More Cost-effective Than Darzalex or Kyprolis for Heavily Treated Myeloma Patients, Study Reports

News

A combination of Pomalyst (pomalidomide) and low-dose dexamethasone is cheaper than either Darzalex (daratumumab) or Kyprolis (carfilzomib) alone as a treatment for relapsed or refractory multiple myeloma (RRMM), a study shows. ... Read more

October 25, 2017

Advanced Myeloma Patients Live Longer Before Disease Worsens on Once-weekly Dose of Kyprolis, ARROW Trial Shows

News

Patients with relapsed and refractory multiple myeloma lived roughly 3.6 months longer without their disease worsening when they received a once-weekly dose of Amgen’s Kyprolis (carfilzomib) compared to a twice-weekly dose, ... Read more

September 6, 2017

Long-term Data Confirms Kyprolis Survival Benefit in Relapsed Myeloma Patients

News

New long-term data from the Phase 3 ENDEAVOR trial has shown that relapsed multiple myeloma patients treated with Kyprolis (carfilzomib) plus dexamethasone survive a median of nine months longer than ... Read more

September 1, 2017

Kyprolis Combo Treatment Extends Survival of Relapsed Myeloma Patients, ENDEAVOR Study Shows

News

Relapsed multiple myeloma patients who receive Kyprolis (carfilzomib) plus dexamethasone as their second-to-fourth treatment regimen survive a median of 7.6 months longer than those given Velcade (bortezomib) and dexamethasone, ... Read more

August 18, 2017August 18, 2017

Scottish Medicines Consortium Approves Kyprolis-Dexamethasone Combo for Previously Treated Multiple Myeloma Patients

News

Combining the proteasome inhibitor Kyprolis (carfilzomib) with dexamethasone is beneficial for adult patients with multiple myeloma who have received at least one prior therapy, the Scottish Medicines Consortium (SMC) determined. ... Read more

July 17, 2017July 17, 2017

Kyprolis-Dexamethasone Combo Allows Relapsed Myeloma Patients to Live Longer, Amgen Says

News

Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with Velcade (bortezomib) with dexamethasone — information that Amgen, which makes Kyprolis, hopes to ... Read more

July 14, 2017July 14, 2017

Kyprolis Regimen Reduces Risk of Death in Relapsed Multiple Myeloma Patients, Studies Show

News

Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and dexamethasone reduced the risk of death in patients with relapsed multiple myeloma by 21%, according ... Read more